Tirzepatide, the dual GIP and GLP-1 receptor agonist behind brand names like Mounjaro and Zepbound, has shown remarkable results in the general population
Nutritional and micronutrient care of bariatric surgery patients: current evidence update
And just like that, the universe said, great, youre all friends now
Conclusion The study supported the content validity of the FCS-SIS symptom items in adults with sHTG
Altogether, when administering GLP-1RA plus SGLT2i combination therapy, it is important to adopt an individualized approach to therapy taking into account individual preferences, costs and coverage, toxicity profile, consideration of kidney function and glucose-lowering efficacy, desire for weight loss, and comorbidities